FATE 241220 2.00P (FATE241220P2000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

FATE241220P2000

Watchlist

0.35
0.000.00%

15min DelayTrading Dec 20 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Fate Therapeutics Announces Executive Leadership Transition
TipRanksJan 6 16:32 ET
Insider Sale: Director at $FATE (FATE) Sells 341,633 Shares
Quiver QuantitativeDec 26, 2024 21:15 ET
Barclays Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $10
Moomoo NewsDec 11, 2024 04:31 ET · Ratings
BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $3
Moomoo NewsDec 10, 2024 05:33 ET · Ratings
Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development
TipRanksDec 10, 2024 04:45 ET · Ratings
Fate Therapeutics Reports FT819 Shows 'Favorable Safety Profile,' Clinical Benefits
MT NewswiresDec 9, 2024 17:41 ET

Comments

105095009

Dec 10, 2024 08:40

$Fate Therapeutics (FATE.US)$ lets go

Jaguar8

Dec 9, 2024 21:04

🟡Watchlist TUESDAY December 10. NFA.

NOTE: There are a lot on my watchlist today which did not yet run. Please do include them in your watchlist up to next week because there are delayed market reactions to news overshadowed by runners.
$Chimerix (CMRX.US)$ PR 12/9 after hours To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End. Ran 100%+ but this is after hour news with conference call tomorrow at 8:30AM ET. May co...

Jaguar8

Dec 9, 2024 15:05

NEWS

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
Fate Therapeutics (NASDAQ: FATE)presented new Phase 1 clinical data for FT819, its off-the-shelf CAR T-cell therapy for systemic lupus erythematosus (SLE). Three patients with active lupus nephritis received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells.
The treatment showed promising ...

Comment allez vous

Nov 26, 2024 08:11

Roche 😙

$Fate Therapeutics (FATE.US)$ Roche buying Fate too?

liang wang199

Nov 18, 2024 11:21

There will be a big rise soon.